In vitro drug interaction studies of atorvastatin with ciprofloxacin, gatifloxacin, and ofloxacin

Medicinal Chemistry Research

Volumn 19, Issue 8, 2010, Pages 717-731

  Arayne, M Saeed ^a   Sultana, Najma ^a   Rizvi, Syeda Bushra Shakeb ^a   Haroon, Urooj ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

Atorvastatin; Charge transfer complex; Ciprofloxacin; Gatifloxacin; Interactions; Ofloxacin

Indexed keywords

ATORSCOT; ATORVASTATIN; CIPROFLOXACIN; GATIFLOXACIN; GLAX; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CALCULATION; COMPLEX FORMATION; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; ENZYME SUBSTRATE; IN VITRO STUDY; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; PH; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ASSAY; TEMPERATURE DEPENDENCE; ULTRAVIOLET SPECTROSCOPY;

EID: 78650719520     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00044-009-9225-5     Document Type: Article

References (41)

1. Agostino F, Rodolfo P (1999) Statins and blockers of the renin-angiotensin system. Hypertension 34:987-996
2. Amsden GW (2002) A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol 42:444-449
3. Arayne MS, Sultana N, Haroon U, Qureshi F (2006) In vitro availability of Atorvastatin in presence of Losartan. Pak J Pharm Sci 19:134-141
4. Arayne MS, Sultana N, Haroon U, Hamza E (2007) In vitro availability studies of enoxacin in presence of H2 receptor antagonists. Pak J Pharm Sci 20:235-243
5. Asberg A (2001) Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. IS J Transplant 1:382-386
6. Black DM (1998) Overview of the clinical safety profile of atorvastatin (Lipitor) a new HMG-CoA reductase inhibitor. Arch Intern Med 158:577-584
7. British Pharmacopia (2005) Her Majesty Stationary Office. 2: A143
8. Chung HS, Woo WS (2001) A quinolone alkaloid with antioxidant activity from the aleurone layer of anthocyanin-pigmented rice. Am Chem Soc Am Soc Pharmacog 64:1579-1580
9. Davis R, Markham A, Balfour JA (1996) Clinical pharmacokinetics of atorvastatin. Drugs 51:1019-1074
10. Dimitra S, Christos GK (2008) Identification and quantitative determination of atorvastatin calcium polymorph in tablets using FT-Raman spectroscopy. Talanta 74:1066-1070
11. Ditusa L, Luzier A (2000) Potential interaction troglitazone and atorvastatin. J Clin Pharm 25:279-282
12. Djurdjevi P, Todorovi M, Stankov MJ, Odovi J (2000) Spectrophotometry determination of ciprofloxacin in serum using iron(III) ionas chromogenic agent. Analyt Lett 33:657-665
13. Du LM, Yang YQ, Wang QM (2004) Spectrofluorometric determination of certain quinolone through charge transfer complex formation. Anal Chim Acta 516:237
14. European Pharmacopia (2005) version 5.0, 5th edn, Council of Europe, 67075. Strasbourg Cedex, France
15. Foroumadi A, Emami S, Mehni M, Moshafi MH, Shafiee A (2005) Synthesis and antibacterial activity of N-[2-(5-bromothiophen-2-yl)-2-oxoethyl] and N-[(2-5-bromothiophen-2-yl)-2-oximinoethyl] derivatives of piperazinyl quinolones. Bioorgan Med Chem Lett 15:4536-4539
16. Grasela DM (2000) Clinical pharmacology of gatifloxacin: a new fluoroquinolone. Clin Infect 31:51-58
17. Hideyuki F, Satoshi H, Keiichi H (1998) Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS- 206584): a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother 42:1917-1922
18. Hirotoshi M, Tsuneo T, Tetsuya S, Hiromi M, Masae M, Kyoji N, Ryozo I (1998) Chemical structure and physico-chemical properties of gatifloxacin hydrate. Iyakuhin Kenkyu 29:885-894
19. Hsyu PH (2001) Pharmacokinetic interaction between nelfinavir and 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 45:3445-3450
20. Iftikhar A, Arayne MS, Sultana N (2005) In vitro release of tetracyclines in presence of H2-receptor antagonists. Pak J Pharm Sci 18:55-60
21. Istvan ES, Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292:1160-1164
22. Joseph L, George M, Rao VR (2008) Simultaneous estimation of atorvastatin and ramipril by RP-HPLC and spectroscopy. Pak J Pharm Sci 21:282-284
23. Kantola T (1998) Effect of intraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64:58-65
24. Kayashi E, Mitsuhashi S (1994) In vitro antibacterial activity of AM-1155, a novel-6 fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 3:594-601
25. Lennernas H (2003) Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141-1160
26. Lewin JJ (2002) Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother 36:1546-1549
27. Lilja JJ (1999) Grape fruit juice increases serum concentration of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 66:118-127
28. Lokesh BVS, Raghava S, Naidu (2007) New dissolution method for the evaluation of enalapril maleate tablets using pH 7.2 phosphate buffer in vitro and determination of its content by validated UV spectrophotometric method. JASA 2:34-37
29. Malinowski J, Am M (1998) Atorvastatin: a 3-hydroxy-3- methylglutarylcoenzymeA-reductase inhibitor. J Health Syst Pharm 55:2253-2267
30. Mazzu AL, Lassester K, Shamblen EC, Agarwal V, Lettieri J, Sunderesen P (2000) Intraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 68:391-400
31. Mohamed SM, Sadek El, Esmail AA (2002) Spectrophotometric determination of ciprofloxacin, enrofloxacin and pefloxacin through charge transfer complex formation. J Pharmaceut Biomed Anal 27:133-142
32. Monk JP, Campoli RDM (1987) Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 33:346-391
33. Mukherjee D, Line-Rogers EK, Fang J, Munir K, Eagle KA (2005) Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart 91:23-26
34. Munson PL, Mueller RA, Breese GR (1995) Principles of pharmacology. Chapman and Hall, New York
35. Ohashi M, Takase H, Sato K, Ueda R, Dohi Y (2005) Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels 20:133-136
36. Radandt JM, Marchbanks CR, Dudley MN (1992) Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infect Dis 14:272-284
37. Renzi R, Finkbeiner S (1991) Ciprofloxacin interaction with sodium warfarin: a potentially dangerous side effect. Am J Emerg Med 9:551-552
38. Sagdinc S, Bayar S (2004) Spectroscopic studies on the interaction of ofloxacin with metals. J Mol Struct 691:107-113
39. Sarkar M, Polk RE, Guzelian PS, Hunt C, Karnes HT (1990) In vitro effect of fluoroquinolones on theophylline metabolism in human liver. Antimicrob Agents Chemother 34:594-599
40. Siedlik PH (1999) Erythromycin coadministration increases plasma atorvastatin concentration. J Clin Pharmacol 39:501-504
41. Wijnands WJ, Vree TB, Van Herwaarden CL (1986) The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol 22:677-683